Sustainable PFAS-free synthesis for pharmaceutical compounds
The novel, environmentally-friendly synthesis strategy holds potential for manufacturing scale up, according to the research.
List view / Grid view
The novel, environmentally-friendly synthesis strategy holds potential for manufacturing scale up, according to the research.
This article discusses the impact of the recent mpox emergency following the outbreak of the virus in 2022, highlights the industry’s response, potential vaccine candidates and key recommendations for international management of the disease.
The first-of-a-kind investment supports the UK government’s objectives to boost clinical trials, improve patient access to novel treatments and increase competitiveness in life sciences.
The multi-target biologic-focused agreement could enhance treatment convenience by improving subcutaneous administration options for patients.
The planned expansion is set to strengthen AstraZeneca’s capability to manufacture biologic medicines for patients globally.
Following its European approval, the small molecule treatment is set to become the standard of care for patients with the ultra-rare disease.
As a promising treatment for type 2 diabetes and obesity, based on key trial data, the market for glucagon-like peptide-1 receptor (GLP-1R) therapies looks set to generate major sales up to 2030.
The analysis technique offers “significant” advantages over traditional colony forming unit (CFU) counts, according to the paper.
The nonIP-RP-LC-MS method provides an “easy, reliable, and cost-effective” approach for bioanalysing oligonucleotide therapies.
The method has potential in both biomanufacturing and production of autologous cell therapies, the research suggests.
The new member of Genmab’s Executive Committee brings over 30 years of international biopharmaceutical experience to the role.
Dr Mehrdad Mobasher, Chief Medical Officer for Hematology, BeiGene, discusses the evolution of therapies for chronic lymphocytic leukaemia (CLL), the promise of targeted treatments and what could be on the horizon of the therapeutic landscape for this disease.
Follow up research to the presented findings could provide improved opportunities for preventing malaria in women during pregnancy.
The biologic treatment targets a key driver of prurigo nodularis, with trial data demonstrating improved itch as well as skin nodules for patients with the condition.
The next-generation B-cell depletion biologic therapy has demonstrated promise in B-cell malignancies and autoimmune diseases.